Fed Circ rejects Sanofi’s bid to resurrect Lantus patents
The US Court of Appeals for the Federal Circuit has rejected several bids from French pharma giant Sanofi to revive claims in its Lantus SoloStar insulin pen patents.
GSK scientist pleads guilty to trade secret theft
Former GlaxoGlaxoSmithKline scientists conspired to steal trade secrets to benefit the Chinese firm, Renopharma, according to the US Department of Justice.
Novartis upholds MS drug patent at Fed Circ
Novartis Pharmaceuticals has prevailed against China’s HEC Pharm at the US Court of Appeals for the Federal Circuit, after a majority panel of judges held that a patent covering the multiple sclerosis drug Gilenya was valid.
InfoBionic wants fees of $2.9m in ‘exceptional’ CardioNet suit
Medical devices company InfoBionic has argued that it should be awarded nearly $2.9 million in fees for attorneys, expenses and expert witnesses.
Oxfam says Moderna hid vaccine dispute from investors
Oxfam America has filed a complaint with the US Securities and Exchange Commission (SEC) claiming that Moderna failed to inform investors that it was in a dispute with the National Institutes of Health over a COVID–19 vaccine patent.
AbbVie wants USITC to investigate Alvotech over Humira ‘theft’
AbbVie seeks to block imports of Alvotech’s biosimilar Humira into the US, claiming that the Icelandic company plundered former employees and used its trade secrets to develop the drug.
Apotex asks Supreme Court to overturn Teva ‘Bendeka’ ruling
Apotex has asked the US Supreme Court to reconsider a US Court of Appeals for the Federal Circuit ruling upholding four of Teva Pharmaceutical’s cancer drug patents.
BioDelivery Sciences ‘pleased’ with mixed ruling over Opioid drug claims
A Delaware Federal Court has upheld some of the validity of challenged claims in two patents related to BioDelivery Sciences’ opioid medication Belbuca, but invalidated others.
NextCure targeted in cancer drug trade secrets suit
Public biopharmaceutical company NextCure has been accused of misappropriating trade secrets in order to create a direct competitor to a biotech’s cancer immunotherapy technology.
Gilead, BMS, Janssen facing HIV generic antitrust suit
Gilead, Bristol-Myers Squibb and Janssen are facing accusations that they suppressed competition in the market for drugs used to treat the human immunodeficiency virus.
